Clinical Trial Update: Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the PET imaging agent [18F]FAPI-74 in gastrointestinal cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Colorectal Cancer
• Gastric Cancer
• Hepatocellular Carcinoma
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• [18F] FAPI-74 (Fluorine-18 labeled fibroblast activation protein inhibitor FAPI-74)

Snippet

Sponsor: SOFIE | Conditions: Gastrointestinal Cancers, Cholangiocarcinoma | Phase 2 | Status: COMPLETED